The Experts below are selected from a list of 9168 Experts worldwide ranked by ideXlab platform
Hidefumi Ito - One of the best experts on this subject based on the ideXlab platform.
-
preventive effect of a heparinoid containing product on the Application Site Reaction of the rotigotine transdermal patch in parkinson s disease a pilot randomized clinical trial the skinhero study
Clinical Parkinsonism & Related Disorders, 2021Co-Authors: Jinsoo Koh, Maiko Takahashi, Mayumi Sakata, Masaaki Yasui, Shoko Yorozu, Hidefumi ItoAbstract:Abstract Introduction The rotigotine transdermal patch (RTP) is a dopamine agonist used to treat Parkinson’s disease (PD) but is sometimes discontinued because of Application Site Reactions (ASRs). We aimed to investigate the effect of a heparinoid-containing product (HCP) for preventing ASRs due to the RTP by conducting a randomized controlled pilot trial. Methods Twenty patients with idiopathic non-demented PD were randomized to the skin care group using a HCP (group H) and the non-skin care group (group N). The primary outcome was the change in the baseline Skindex-16 score (ΔSkindex-16) at week 4. In addition, skin symptoms were also evaluated using the Dermatology Life Quality Index (DLQI) and International Contact Dermatitis Research Group (ICDRG) system for clinical scoring allergic patch test Reactions up to week 8. Results The ΔSkindex-16 score at week 4 tended to be lower in group H than in group N, although the difference was not statistically significant (−1.5 ± 2.0 vs 1.3 ± 10.9, p = 0.53). When the patients with baseline Skindex-16 scores ≥ 7 were excluded, the ΔSkindex-16 at week 4 was significantly lower in group H (−1.5 ± 2.0 vs 6.1 ± 8.6, p = 0.042). The DLQI also tended to be lower in group H at weeks 4 and 8, but not significantly (p = 0.066 and p = 0.077, respectively). The ICDRG score at week 4 was significantly lower in group H (p = 0.044). Conclusion We suggest that the HCP has a preventive effect against ASRs cause by the RTP.
Jinsoo Koh - One of the best experts on this subject based on the ideXlab platform.
-
preventive effect of a heparinoid containing product on the Application Site Reaction of the rotigotine transdermal patch in parkinson s disease a pilot randomized clinical trial the skinhero study
Clinical Parkinsonism & Related Disorders, 2021Co-Authors: Jinsoo Koh, Maiko Takahashi, Mayumi Sakata, Masaaki Yasui, Shoko Yorozu, Hidefumi ItoAbstract:Abstract Introduction The rotigotine transdermal patch (RTP) is a dopamine agonist used to treat Parkinson’s disease (PD) but is sometimes discontinued because of Application Site Reactions (ASRs). We aimed to investigate the effect of a heparinoid-containing product (HCP) for preventing ASRs due to the RTP by conducting a randomized controlled pilot trial. Methods Twenty patients with idiopathic non-demented PD were randomized to the skin care group using a HCP (group H) and the non-skin care group (group N). The primary outcome was the change in the baseline Skindex-16 score (ΔSkindex-16) at week 4. In addition, skin symptoms were also evaluated using the Dermatology Life Quality Index (DLQI) and International Contact Dermatitis Research Group (ICDRG) system for clinical scoring allergic patch test Reactions up to week 8. Results The ΔSkindex-16 score at week 4 tended to be lower in group H than in group N, although the difference was not statistically significant (−1.5 ± 2.0 vs 1.3 ± 10.9, p = 0.53). When the patients with baseline Skindex-16 scores ≥ 7 were excluded, the ΔSkindex-16 at week 4 was significantly lower in group H (−1.5 ± 2.0 vs 6.1 ± 8.6, p = 0.042). The DLQI also tended to be lower in group H at weeks 4 and 8, but not significantly (p = 0.066 and p = 0.077, respectively). The ICDRG score at week 4 was significantly lower in group H (p = 0.044). Conclusion We suggest that the HCP has a preventive effect against ASRs cause by the RTP.
Jay D Amsterdam - One of the best experts on this subject based on the ideXlab platform.
-
a double blind placebo controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder
The Journal of Clinical Psychiatry, 2003Co-Authors: Jay D AmsterdamAbstract:BACKGROUND: The monoamine oxidase (MAO) inhibitor selegiline has demonstrated antidepressant efficacy superior to placebo. A selegiline transdermal system (STS) has been developed with unique pharmacokinetic and pharmacodynamic properties that allow inhibition of central nervous system MAO-A and MAO-B enzymes while substantially avoiding inhibition of intestinal and liver MAO-A enzyme. This novel transdermal system provides targeted MAO inhibition without clinically significant increases in sensitivity to dietary tyramine. We investigated the safety and efficacy of STS in patients with major depressive disorder. METHOD: 365 outpatients 18 to 65 years old with a DSM-IV diagnosis of major depressive disorder were enrolled at 16 Sites. A 17-item Hamilton Rating Scale for Depression (HAM-D-17) score of > or = 20 was required for entry. Patients were randomly assigned to receive either STS, 20 mg/20 cm(2), daily or placebo patch for up to 8 weeks. A tyramine-restricted diet was neither required nor advised. Efficacy, safety, and vital sign measures were obtained regularly. RESULTS: 289 patients were randomly assigned to treatment and received at least 1 on-therapy evaluation (STS, N = 145; placebo, N = 144). Although the effect size was modest, at endpoint, STS was statistically superior to placebo on the MADRS (p =.001) and HAM-D-28 (p =.039) ratings and showed a nonsignificant superiority on the HAM-D-17 (p =.069) and Clinical Global Impressions-Severity ratings (p <.055). Side effect profiles were similar for STS and placebo with the exception of Application-Site Reaction, which was observed in 31.5% of STS patients and 15.1% of placebo-treated patients (p =.001). No significant differences were observed in blood pressure measures between treatment groups. CONCLUSION: Results from this double-blind, placebo-controlled clinical trial demonstrate that STS may have a modest, but statistically significant, antidepressant benefit compared with placebo and a similar safety profile compared with placebo in the absence of a tyramine-restricted diet.
Mayumi Sakata - One of the best experts on this subject based on the ideXlab platform.
-
preventive effect of a heparinoid containing product on the Application Site Reaction of the rotigotine transdermal patch in parkinson s disease a pilot randomized clinical trial the skinhero study
Clinical Parkinsonism & Related Disorders, 2021Co-Authors: Jinsoo Koh, Maiko Takahashi, Mayumi Sakata, Masaaki Yasui, Shoko Yorozu, Hidefumi ItoAbstract:Abstract Introduction The rotigotine transdermal patch (RTP) is a dopamine agonist used to treat Parkinson’s disease (PD) but is sometimes discontinued because of Application Site Reactions (ASRs). We aimed to investigate the effect of a heparinoid-containing product (HCP) for preventing ASRs due to the RTP by conducting a randomized controlled pilot trial. Methods Twenty patients with idiopathic non-demented PD were randomized to the skin care group using a HCP (group H) and the non-skin care group (group N). The primary outcome was the change in the baseline Skindex-16 score (ΔSkindex-16) at week 4. In addition, skin symptoms were also evaluated using the Dermatology Life Quality Index (DLQI) and International Contact Dermatitis Research Group (ICDRG) system for clinical scoring allergic patch test Reactions up to week 8. Results The ΔSkindex-16 score at week 4 tended to be lower in group H than in group N, although the difference was not statistically significant (−1.5 ± 2.0 vs 1.3 ± 10.9, p = 0.53). When the patients with baseline Skindex-16 scores ≥ 7 were excluded, the ΔSkindex-16 at week 4 was significantly lower in group H (−1.5 ± 2.0 vs 6.1 ± 8.6, p = 0.042). The DLQI also tended to be lower in group H at weeks 4 and 8, but not significantly (p = 0.066 and p = 0.077, respectively). The ICDRG score at week 4 was significantly lower in group H (p = 0.044). Conclusion We suggest that the HCP has a preventive effect against ASRs cause by the RTP.
Masaaki Yasui - One of the best experts on this subject based on the ideXlab platform.
-
preventive effect of a heparinoid containing product on the Application Site Reaction of the rotigotine transdermal patch in parkinson s disease a pilot randomized clinical trial the skinhero study
Clinical Parkinsonism & Related Disorders, 2021Co-Authors: Jinsoo Koh, Maiko Takahashi, Mayumi Sakata, Masaaki Yasui, Shoko Yorozu, Hidefumi ItoAbstract:Abstract Introduction The rotigotine transdermal patch (RTP) is a dopamine agonist used to treat Parkinson’s disease (PD) but is sometimes discontinued because of Application Site Reactions (ASRs). We aimed to investigate the effect of a heparinoid-containing product (HCP) for preventing ASRs due to the RTP by conducting a randomized controlled pilot trial. Methods Twenty patients with idiopathic non-demented PD were randomized to the skin care group using a HCP (group H) and the non-skin care group (group N). The primary outcome was the change in the baseline Skindex-16 score (ΔSkindex-16) at week 4. In addition, skin symptoms were also evaluated using the Dermatology Life Quality Index (DLQI) and International Contact Dermatitis Research Group (ICDRG) system for clinical scoring allergic patch test Reactions up to week 8. Results The ΔSkindex-16 score at week 4 tended to be lower in group H than in group N, although the difference was not statistically significant (−1.5 ± 2.0 vs 1.3 ± 10.9, p = 0.53). When the patients with baseline Skindex-16 scores ≥ 7 were excluded, the ΔSkindex-16 at week 4 was significantly lower in group H (−1.5 ± 2.0 vs 6.1 ± 8.6, p = 0.042). The DLQI also tended to be lower in group H at weeks 4 and 8, but not significantly (p = 0.066 and p = 0.077, respectively). The ICDRG score at week 4 was significantly lower in group H (p = 0.044). Conclusion We suggest that the HCP has a preventive effect against ASRs cause by the RTP.